Saitama Children's Medical Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sosa, Favio Edmundo Enriquez
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
Cornejo, Gabriel Vega
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, not recruiting
3
100
Europe, RoW
Ixekizumab, LY2439821, Adalimumab
Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
02/24
04/28
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Iwama, Itaru
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
Tommasini, Alberto
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
NCT05803356: Genetic and Immunologic Characterization of IEI

Completed
N/A
156
Europe
IRCCS Burlo Garofolo
Immunity Disorders, Inborn Errors of Immunity
12/22
12/22
NCT06324578: Prevalence of Pre-clinical Sjögren Disease and Other Immune Disturbances in Subjects With Autoimmune Thyroiditis Disease

Recruiting
N/A
150
Europe
AT Testing
IRCCS Burlo Garofolo
Sjögren, Autoimmune Thyroid Disease
12/25
12/25
Sato, Satoshi
NCT05814159: A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Active, not recruiting
3
15
Japan
Anakinra, Kineret, Placebo
Swedish Orphan Biovitrum, CMIC Co, Ltd. Japan
Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
12/25
06/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Fujinaga, Shuichiro
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD

Terminated
3
270
Europe, Japan, US, RoW
Bardoxolone methyl, RTA 402
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
08/23
08/23
ASCEND-P, NCT05682326 / 2021-002013-34: Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric

Active, not recruiting
3
75
Japan, US, RoW
Daprodustat
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GSK Research & Development Limited
Anaemia
07/30
07/30

Download Options